Trial Profile
Randomized contro trial of Endostar in deferent time combined with DP regime for IIIB-IV stage NSCLC
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Endostatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 May 2012 Planned end date (31 Dec 2012) added as reported by Chinese Clinical Trial Register record.
- 25 Jan 2012 New trial record